Steven Hamlen, MBA, and Nicholas Johnson, PhD, MBA, discuss recent technology innovations in controlled-release solid oral dose functions and forms as well as more established methods for altering release profiles of molecules, and provide a real-world case study in which applying alternative formulation technology significantly improved an existing therapy and delivered patient and payer benefits.
PACKAGING SOLUTIONS – Overcoming the Challenges of Child-Resistant/Senior-Friendly Closure Development in Today’s Changing World
Steve Stalions and Kurt Attermeier say that as the demand for better CR/SF packaging is on the rise, so too is the market demand for greater cost effectiveness, sustainability, and value-added end-user benefits, and explain how these challenges can be overcome.
ABUSE DETERRENT TECHNOLOGY – New Abuse Deterrent Formulation Technology for Immediate-Release Opioids
Johannes Bartholomäus͛, PhD; Sebastian Schwier, PhD; Martin Brett, et al, review how the INTAC technology platform has been extended to IR formulations with the intention to deter non-oral routes of abuse.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part II of III
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
Alan Shortall believes with dual-chamber syringes and other emerging device technologies now addressing key market requirements for intuitive reconstitution and injection, the pharmaceutical market for therapies suitable for reconstitution and mixing at the point of delivery is poised for significant rates of growth.
Drug Development Executive: Vincent D. Antle, PhD, Senior Director of Technical Operations, and James D. Pipkin, PhD, Senior Director, New Product Development talk about how the company works closely with pharmaceutical and biotechnology companies offering drug delivery solutions that significantly improve stability, solubility, bioavailability, safety, and dosing of APIs.
Contributor Cindy H. Dubin highlights in this annual report that new devices are coming to market that not only address the trends of home care and a need for delivering larger doses, but are also cleaning up the spotty reputation of early stage devices.
Lawrence Acquarulo, PhD, indicates an increased availability of certain medical materials could create a new wave in the development of precision devices to reach smaller areas deeper within the body.
Drug Development Executive: Amit Patel, President of Capsugel’s Dosage Form Solutions business unit, speaks about the formulation challenges facing the industry and the increasing pressure on companies to remain competitive in today’s dynamic marketplace.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part I of III
In the past two columns, The Second Quadrant focused on excipients and the roles they play in the quest to overcome bioavailability challenges of poorly…
EXCLUSIVE ONLINE CONTENT
TriSalus Life Sciences & Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology
TriSalus Life Sciences recently announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its…..
Alkahest, Inc. recently announced the initiation of a Phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first….
Credence MedSystems, an innovator in injectable drug delivery technology for the biopharmaceutical industry, has received the Pharmapack Award for its….
Aptar Pharma recently announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the US FDA as a rescue treatment for….
Codexis, Inc. and Nestlé Health Science have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement (SCA) into preclinical….